Dual-Phase Medium-Chain Triglyceride Intervention

Target: HMGCS2/CPT1A Composite Score: 0.540 Price: $0.61▲17.0% Citation Quality: Pending neurodegeneration Status: promoted
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
📄 Export → LaTeX
Select venue
arXiv Preprint NeurIPS Nature Methods PLOS ONE
🌐 Open in Overleaf →
📖 Export BibTeX
🔴 Alzheimer's Disease 🧠 Neurodegeneration 🔥 Neuroinflammation
✓ All Quality Gates Passed
Evidence Strength Pending (0%)
8
Citations
1
Debates
6
Supporting
2
Opposing
Quality Report Card click to collapse
C+
Composite: 0.540
Top 60% of 1875 hypotheses
T2 Supported
Literature-backed with debate validation
Needs convergence ≥0.40 (current: 0.00) for Established
B Mech. Plausibility 15% 0.60 Top 57%
B+ Evidence Strength 15% 0.70 Top 20%
C Novelty 12% 0.45 Top 92%
A Feasibility 12% 0.85 Top 21%
B+ Impact 12% 0.70 Top 51%
C+ Druggability 10% 0.50 Top 57%
C+ Safety Profile 8% 0.50 Top 57%
C Competition 6% 0.47 Top 88%
B+ Data Availability 5% 0.78 Top 25%
D Reproducibility 5% 0.25 Top 94%
Evidence
6 supporting | 2 opposing
Citation quality: 65%
Debates
1 session A+
Avg quality: 0.93
Convergence
0.00 F 30 related hypothesis share this target

From Analysis:

How do astrocyte-neuron metabolic interactions change during disease progression in neurodegeneration?

The glial ketone shunt hypothesis raised questions about astrocytic metabolic reprogramming affecting neuronal fuel supply, but the temporal dynamics and cell-type specificity remain unexplored. This gap limits understanding of when metabolic interventions might be most effective. Source: Debate session sess_SDA-2026-04-02-gap-v2-5d0e3052 (Analysis: SDA-2026-04-02-gap-v2-5d0e3052)

→ View full analysis & debate transcript

Description

Molecular Mechanism and Rationale

The dual-phase medium-chain triglyceride (MCT) intervention targets key enzymes in ketogenic metabolism, specifically 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2) and carnitine palmitoyltransferase 1A (CPT1A), to address the progressive metabolic dysfunction underlying neurodegeneration. HMGCS2, the rate-limiting enzyme in ketogenesis, catalyzes the condensation of acetoacetyl-CoA and acetyl-CoA to form HMG-CoA, which is subsequently converted to ketone bodies. In the early phase, C8-C10 MCTs rapidly generate acetyl-CoA through beta-oxidation, saturating HMGCS2 activity and maximizing ketone production. This upregulation occurs primarily in hepatic mitochondria and astrocytes, where HMGCS2 expression is highest.

...

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["DAMPs / PAMPs Detection"] --> B["NLRP3 Inflammasome Assembly"]
    B --> C["Caspase-1 Activation"]
    C --> D["GSDMD Cleavage"]
    D --> E["Membrane Pore Formation"]
    E --> F["IL-1β / IL-18 Release"]
    F --> G["Pyroptotic Cell Death"]
    H["HMGCS2 Intervention"] --> I["Inflammasome Inhibition"]
    I --> J["Blocked Pyroptosis"]
    J --> K["Reduced Neuroinflammation"]
    style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style H fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style K fill:#1b5e20,stroke:#81c784,color:#81c784

GTEx v10 Brain Expression

JSON

Median TPM across 13 brain regions for HMGCS2/CPT1A from GTEx v10.

Substantia nigra0.2 Cerebellum0.1 Hypothalamus0.1 Cerebellar Hemisphere0.1 Cortex0.1 Spinal cord cervical c-10.0 Caudate basal ganglia0.0 Hippocampus0.0 Frontal Cortex BA90.0 Nucleus accumbens basal ganglia0.0 Anterior cingulate cortex BA240.0 Putamen basal ganglia0.0 Amygdala0.0median TPM (GTEx v10)

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.60 (15%) Evidence 0.70 (15%) Novelty 0.45 (12%) Feasibility 0.85 (12%) Impact 0.70 (12%) Druggability 0.50 (10%) Safety 0.50 (8%) Competition 0.47 (6%) Data Avail. 0.78 (5%) Reproducible 0.25 (5%) KG Connect 0.15 (8%) 0.540 composite
8 citations 8 with PMID Validation: 65% 6 supporting / 2 opposing
For (6)
No supporting evidence
No opposing evidence
(2) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
6
1
1
MECH 6CLIN 1GENE 0EPID 1
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
Different MCFAs have distinct effects on astrocyte…SupportingMECH----PMID:26839375-
Temporal metabolic reprogramming distinguishes neu…SupportingMECH----PMID:30930170-
Regulation of energy metabolism by long-chain fatt…SupportingMECHProg Lipid Res-2014-PMID:24362249-
Fatty acid metabolism can cause mitochondrial dama…OpposingMECH----PMID:9215876-
Ketogenesis acts as an endogenous protective progr…OpposingEPIDEBioMedicine-2022-PMID:35339899-
Tubule-Specific Compensatory Responses to Cpt1a De…SupportingMECHKidney360 MODERATE2025-PMID:40138521-
Downregulation of HMGCS2 mediated AECIIs lipid met…SupportingMECHRespir Res MODERATE2024-PMID:38658970-
Minimum Dietary Fat Threshold for Effective Ketoge…SupportingCLINNutrients MODERATE2025-PMID:41156456-
Legacy Card View — expandable citation cards

Supporting Evidence 6

Different MCFAs have distinct effects on astrocyte metabolism - decanoic acid promotes glycolysis while octano…
Different MCFAs have distinct effects on astrocyte metabolism - decanoic acid promotes glycolysis while octanoic acid increases ketogenesis
Temporal metabolic reprogramming distinguishes neuronal susceptibility
Regulation of energy metabolism by long-chain fatty acids.
Prog Lipid Res · 2014 · PMID:24362249
Tubule-Specific Compensatory Responses to Cpt1a Deletion in Aged Mice MODERATE
Kidney360 · 2025 · PMID:40138521
Downregulation of HMGCS2 mediated AECIIs lipid metabolic alteration promotes pulmonary fibrosis by activating … MODERATE
Downregulation of HMGCS2 mediated AECIIs lipid metabolic alteration promotes pulmonary fibrosis by activating fibroblasts
Respir Res · 2024 · PMID:38658970
Minimum Dietary Fat Threshold for Effective Ketogenesis and Obesity Control in Mice MODERATE
Nutrients · 2025 · PMID:41156456

Opposing Evidence 2

Fatty acid metabolism can cause mitochondrial damage in brain cultures when exposed to neurotoxins
Ketogenesis acts as an endogenous protective programme to restrain inflammatory macrophage activation during a…
Ketogenesis acts as an endogenous protective programme to restrain inflammatory macrophage activation during acute pancreatitis.
EBioMedicine · 2022 · PMID:35339899
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-04 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Based on the glial ketone shunt hypothesis and astrocyte-neuron metabolic interactions in neurodegeneration, here are 7 novel therapeutic hypotheses:

Hypothesis 1: Temporal Metabolic Window Therapy

Description: There exists a critical therapeutic window early in neurodegeneration where astrocytic ketone production is declining but neurons retain ketone oxidation capacity. Targeted ketone supplementation during this specific phase could restore metabolic coupling and prevent irreversible neuronal damage.

Target gene/protein: HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2) - key

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

Strong Counter-evidence: PMID:37686202 and others show lactate is neuroprotective and essential for brain function, not harmful. The astrocyte-neuron lactate shuttle is a well-established neuroprotective mechanism.

Alternative explanations:

  • Lactate may be compensatory and beneficial in neurodegeneration
  • The metabolic shift may be adaptive rather than pathological
Falsification experiment: Compare outcomes in disease models with and without lactate production, and test whether lactate supplementation is neuroprotective.

Hypothesis 7: Astrocyte Fuel Preference Pharmacogeno

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

Based on my analysis of the hypotheses and the available data, here's my practical feasibility assessment:

FEASIBILITY ASSESSMENT

Hypothesis 1: Temporal Metabolic Window Therapy (HMGCS2 targeting)

Druggability: MODERATE ⭐⭐⭐☆☆

Existing Chemical Matter:

  • Ketone esters (e.g., (R)-3-hydroxybutyl (R)-3-hydroxybutyrate) - Already in clinical use
  • Medium-chain triglycerides (MCTs) - Available supplements that promote ketogenesis
  • Beta-hydroxybutyrate salts - Commercially available
Clinical Trials:
  • NCT04701957: Ketogenic Diet for Alzheimer's Disease (rec

Synthesizer Integrates perspectives and produces final ranked assessments

Price History

0.470.530.60 score_update: market_dynamics (2026-04-12T04:59)debate: market_dynamics (2026-04-12T05:17)evidence: market_dynamics (2026-04-12T05:39)debate: market_dynamics (2026-04-12T05:58)score_update: market_dynamics (2026-04-12T06:21)evidence: market_dynamics (2026-04-12T07:44)debate: market_dynamics (2026-04-12T10:26)evidence: market_dynamics (2026-04-12T11:18)score_update: market_dynamics (2026-04-12T13:36)evidence: evidence_batch_update (2026-04-13T02:18)evidence: evidence_batch_update (2026-04-13T02:18) 0.66 0.40 2026-04-122026-04-132026-04-27 Market PriceScoreevidencedebate 74 events
7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Medium
0.0343
Events (7d)
3
⚡ Price Movement Log Recent 12 events
Event Price Change Source Time
📄 New Evidence $0.533 ▲ 1.5% evidence_batch_update 2026-04-13 02:18
📄 New Evidence $0.525 ▲ 17.5% evidence_batch_update 2026-04-13 02:18
📊 Score Update $0.447 ▼ 19.4% market_dynamics 2026-04-12 13:36
📄 New Evidence $0.555 ▲ 31.2% market_dynamics 2026-04-12 11:18
💬 Debate Round $0.423 ▼ 20.2% market_dynamics 2026-04-12 10:26
📄 New Evidence $0.530 ▲ 8.8% market_dynamics 2026-04-12 07:44
📊 Score Update $0.487 ▼ 0.3% market_dynamics 2026-04-12 06:21
💬 Debate Round $0.489 ▼ 12.3% market_dynamics 2026-04-12 05:58
📄 New Evidence $0.557 ▲ 7.8% market_dynamics 2026-04-12 05:39
💬 Debate Round $0.517 ▲ 2.2% market_dynamics 2026-04-12 05:17
Recalibrated $0.506 ▼ 12.0% 2026-04-12 05:13
📊 Score Update $0.575 market_dynamics 2026-04-12 04:59

Clinical Trials (0) Relevance: 57%

No clinical trials data available

📚 Cited Papers (11)

Regulation of energy metabolism by long-chain fatty acids.
Progress in lipid research (2014) · PMID:24362249
No extracted figures yet
Medium-chain fatty acids inhibit mitochondrial metabolism in astrocytes promoting astrocyte-neuron lactate and ketone body shuttle systems.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2017) · PMID:26839375
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (0)

No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Low Efficiency Resource Efficiency Score
0.39
17.1th percentile (776 hypotheses)
Tokens Used
5,905
KG Edges Generated
3
Citations Produced
8

Cost Ratios

Cost per KG Edge
984.17 tokens
Lower is better (baseline: 2000)
Cost per Citation
738.12 tokens
Lower is better (baseline: 1000)
Cost per Score Point
10111.30 tokens
Tokens / composite_score

Score Impact

Efficiency Boost to Composite
+0.039
10% weight of efficiency score
Adjusted Composite
0.578

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Efficiency Price Signals

Date Signal Price Score
2026-04-17T09:10$0.6100.494

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for HMGCS2/CPT1A.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for HMGCS2/CPT1A →
Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

KG Entities (40)

Astrocyte fuel preference resetAstrocyte ketogenesisAstrocyte metabolic reprogrammingAstrocyte mitochondrial biogenesisAstrocyte-neuron lactate shuttleAstrocyte-neuron lactate shuttle disruptAstrocytic ketogenesis declineBeta-hydroxybutyrate elevationBrain functionEarly neurodegenerationEpigenetic modulatorsHMGCS2HMGCS2/CPT1AKetogenic dietKetone estersKetone supplementationLDHA inhibitionLactateLong-term safety concernsMIB-626

Linked Experiments (1)

High fat diet aging study in CPT1A knockout micevalidation | tests | 0.85

Related Hypotheses

Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration
Score: 0.907 | neurodegeneration
Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse
Score: 0.895 | neurodegeneration
SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence
Score: 0.893 | neurodegeneration
TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration
Score: 0.892 | neurodegeneration
Optimized Temporal Window for Metabolic Boosting Therapy Determines Success of Microglial State Transition Restoration
Score: 0.887 | neurodegeneration

Estimated Development

Estimated Cost
$0
Timeline
8.0 years

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified
IF 5xFAD transgenic mice receive oral C8-C10 MCT oil at 15% caloric intake for 12 weeks, THEN plasma β-hydroxybutyrate will increase by ≥0.8 mM above baseline AND Morris water maze escape latency will decrease by ≥30% compared to vehicle-treated controls, within 12 weeks of intervention.
pending conf: 0.75
Expected outcome: Plasma β-hydroxybutyrate ≥0.8 mM above baseline; Morris water maze escape latency ≥30% improvement
Falsified by: Plasma β-hydroxybutyrate increases <0.4 mM above baseline OR Morris water maze performance shows no significant improvement (p>0.05) despite elevated ketones
Method: Randomized controlled trial in 12-week-old male 5xFAD mice (n=20/group), comparing C8-C10 MCT oil (15% kcal) vs. vehicle (saline) over 12 weeks, with plasma ketone measurements at weeks 0, 4, 8, 12 and behavioral testing at baseline and week 12
IF APP/PS1 double transgenic mice receive dual-phase MCT (C8-C10 for weeks 0-12, transitioning to C6-C8 for weeks 12-24) compared to single-phase C8-C10 MCT for 24 weeks, THEN dual-phase intervention will demonstrate ≥25% greater reduction in hippocampal amyloid-beta plaque burden measured by immunohistochemistry, within 24 weeks total.
pending conf: 0.65
Expected outcome: Hippocampal amyloid-beta plaque burden ≥25% lower in dual-phase vs. single-phase group
Falsified by: No significant difference in amyloid-beta plaque burden between dual-phase and single-phase groups (p>0.05), OR dual-phase shows ≥10% higher plaque burden than single-phase
Method: Parallel-arm randomized trial in 6-month-old APP/PS1 mice (n=15/group), dual-phase MCT vs. single-phase C8-C10 MCT at 15% caloric intake, with stereological quantification of Thioflavin-S positive plaques in hippocampus at 24 weeks

Knowledge Subgraph (24 edges)

activates (1)

PPARGC1AAstrocyte mitochondrial biogenesis

associated with (1)

HMGCS2/CPT1Aneurodegeneration

biomarker for (1)

Neurons retain ketone oxidation capacityTherapeutic window

causal extracted (1)

sess_SDA-2026-04-04-SDA-2026-04-04-gap-debate-20260403-222618-e6a431ddprocessed

causes (8)

Ketone estersNeuroprotectionAstrocytic ketogenesis declineNeurodegenerationAstrocyte-neuron lactate shuttleBrain functionPathological glycolysisNeurodegenerationKetogenic dietBeta-hydroxybutyrate elevation
▸ Show 3 more

involved in (1)

HMGCS2ketogenesis___astrocyte_ketone_body_utilization

modulates (1)

PGC1α activationNeuronal metabolic support

protective against (2)

LactateNeuroprotectionKetone estersNeurodegeneration

regulates (3)

HMGCS2Astrocyte ketogenesisSIRT1Astrocyte metabolic reprogrammingSLC16A7Neuronal glucose uptake

risk factor for (1)

Early neurodegenerationTherapeutic window availability

targets (1)

h-edfd6c89HMGCS2/CPT1A

therapeutic target for (3)

Ketone supplementationMetabolic coupling restorationEpigenetic modulatorsAstrocyte fuel preference resetKetone supplementationNeurodegeneration prevention

Mechanism Pathway for HMGCS2/CPT1A

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    HMGCS2["HMGCS2"] -->|regulates| Astrocyte_ketogenesis["Astrocyte ketogenesis"]
    Lactate["Lactate"] -->|protective against| Neuroprotection["Neuroprotection"]
    Ketogenic_diet["Ketogenic diet"] -->|causes| Beta_hydroxybutyrate_elev["Beta-hydroxybutyrate elevation"]
    Ketone_esters["Ketone esters"] -->|causes| Neuroprotection_1["Neuroprotection"]
    Astrocytic_ketogenesis_de["Astrocytic ketogenesis decline"] -->|causes| Neurodegeneration["Neurodegeneration"]
    Ketone_supplementation["Ketone supplementation"] -->|therapeutic target| Metabolic_coupling_restor["Metabolic coupling restoration"]
    SIRT1["SIRT1"] -->|regulates| Astrocyte_metabolic_repro["Astrocyte metabolic reprogramming"]
    PPARGC1A["PPARGC1A"] -->|activates| Astrocyte_mitochondrial_b["Astrocyte mitochondrial biogenesis"]
    Astrocyte_neuron_lactate_["Astrocyte-neuron lactate shuttle"] -->|causes| Brain_function["Brain function"]
    Pathological_glycolysis["Pathological glycolysis"] -->|causes| Neurodegeneration_2["Neurodegeneration"]
    Epigenetic_modulators["Epigenetic modulators"] -->|therapeutic target| Astrocyte_fuel_preference["Astrocyte fuel preference reset"]
    Neurons_retain_ketone_oxi["Neurons retain ketone oxidation capacity"] -->|biomarker for| Therapeutic_window["Therapeutic window"]
    style HMGCS2 fill:#ce93d8,stroke:#333,color:#000
    style Astrocyte_ketogenesis fill:#4fc3f7,stroke:#333,color:#000
    style Lactate fill:#4fc3f7,stroke:#333,color:#000
    style Neuroprotection fill:#4fc3f7,stroke:#333,color:#000
    style Ketogenic_diet fill:#4fc3f7,stroke:#333,color:#000
    style Beta_hydroxybutyrate_elev fill:#4fc3f7,stroke:#333,color:#000
    style Ketone_esters fill:#4fc3f7,stroke:#333,color:#000
    style Neuroprotection_1 fill:#4fc3f7,stroke:#333,color:#000
    style Astrocytic_ketogenesis_de fill:#4fc3f7,stroke:#333,color:#000
    style Neurodegeneration fill:#ef5350,stroke:#333,color:#000
    style Ketone_supplementation fill:#4fc3f7,stroke:#333,color:#000
    style Metabolic_coupling_restor fill:#4fc3f7,stroke:#333,color:#000
    style SIRT1 fill:#4fc3f7,stroke:#333,color:#000
    style Astrocyte_metabolic_repro fill:#4fc3f7,stroke:#333,color:#000
    style PPARGC1A fill:#ce93d8,stroke:#333,color:#000
    style Astrocyte_mitochondrial_b fill:#4fc3f7,stroke:#333,color:#000
    style Astrocyte_neuron_lactate_ fill:#81c784,stroke:#333,color:#000
    style Brain_function fill:#4fc3f7,stroke:#333,color:#000
    style Pathological_glycolysis fill:#4fc3f7,stroke:#333,color:#000
    style Neurodegeneration_2 fill:#ef5350,stroke:#333,color:#000
    style Epigenetic_modulators fill:#4fc3f7,stroke:#333,color:#000
    style Astrocyte_fuel_preference fill:#4fc3f7,stroke:#333,color:#000
    style Neurons_retain_ketone_oxi fill:#4fc3f7,stroke:#333,color:#000
    style Therapeutic_window fill:#4fc3f7,stroke:#333,color:#000

3D Protein Structure

🧬 HMGCS2 — PDB 2WYA Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

How do astrocyte-neuron metabolic interactions change during disease progression in neurodegeneration?

neurodegeneration | 2026-04-04 | archived

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (2)

Astrocyte Metabolic Memory Reprogramming
Score: 0.54 · SIRT1
Temporal Metabolic Window Therapy
Score: 0.53 · HMGCS2
→ View all analysis hypotheses
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.